Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G.

BMC Cancer. 2019 Sep 9;19(1):899. doi: 10.1186/s12885-019-6109-z.

2.

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.

Ottaiano A, Capozzi M, Tafuto S, De Stefano A, De Divitiis C, Romano C, Avallone A, Nasti G.

Front Oncol. 2019 Aug 13;9:766. doi: 10.3389/fonc.2019.00766. eCollection 2019.

3.

Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms.

von Arx C, Capozzi M, López-Jiménez E, Ottaiano A, Tatangelo F, Di Mauro A, Nasti G, Tornesello ML, Tafuto S.

J Clin Med. 2019 Aug 22;8(9). pii: E1277. doi: 10.3390/jcm8091277. Review.

4.

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.

Tafuto S, von Arx C, Capozzi M, Tatangelo F, Mura M, Modica R, Barretta ML, Di Sarno A, Tornesello ML, Colao A, Ottaiano A.

J Clin Med. 2019 Aug 15;8(8). pii: E1224. doi: 10.3390/jcm8081224.

5.

Metastatic Colorectal Cancer: Prognostic And Predictive Factors.

Nappi A, Nasti G, Romano C, Berretta M, Ottaiano A.

Curr Med Chem. 2019 Jun 20. doi: 10.2174/0929867326666190620110732. [Epub ahead of print]

PMID:
31218949
6.

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment.

Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S.

Cancer Manag Res. 2019 May 1;11:3847-3860. doi: 10.2147/CMAR.S188316. eCollection 2019. Review.

7.

Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors.

Ottaiano A, Scotti V, De Divitiis C, Capozzi M, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Vicario V, De Stefano A, Tafuto S, Berretta M, Nasti G, Avallone A.

Oncotarget. 2018 Oct 16;9(81):35251-35265. doi: 10.18632/oncotarget.25834. eCollection 2018 Oct 16.

8.

Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples.

Capozzi M, De Divitiis C, Ottaiano A, Teresa T, Capuozzo M, Maiolino P, Botti G, Tafuto S, Avallone A; Abdominal Oncology Group.

Front Public Health. 2018 Oct 12;6:291. doi: 10.3389/fpubh.2018.00291. eCollection 2018.

9.

Real practice studies in oncology: A positive perspective.

Ottaiano A.

World J Gastrointest Oncol. 2018 Sep 15;10(9):228-230. doi: 10.4251/wjgo.v10.i9.228.

10.

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.

Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A.

Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Review.

11.

Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?

Ottaiano A, Cassata A, Capozzi M, De Divitiis C, De Stefano A, Avallone A.

Front Oncol. 2018 Mar 14;8:62. doi: 10.3389/fonc.2018.00062. eCollection 2018.

12.

Can the addition of radiotherapy postoperatively increase clinical outcome of patients with gastric cancer? A systematic review of the literature and meta-analysis.

Fiorica F, Trovò M, Ottaiano A, Nasti G, Carandina I, Marzola M, De Paoli P, Berretta M.

Oncotarget. 2017 Dec 28;9(12):10734-10744. doi: 10.18632/oncotarget.23754. eCollection 2018 Feb 13.

13.

Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy.

Ottaiano A, Napolitano M, Capozzi M, Tafuto S, Avallone A, Scala S.

World J Clin Cases. 2017 Nov 16;5(11):390-396. doi: 10.12998/wjcc.v5.i11.390.

14.

FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.

Ottaiano A, Nasti G, Cassata A, De Stefano A, Caraglia M, Avallone A.

Cancer Lett. 2017 Nov 1;408:71-72. doi: 10.1016/j.canlet.2017.08.025. Epub 2017 Aug 24. No abstract available.

PMID:
28844712
15.

Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.

Ottaiano A, Capozzi M, DE Divitiis C, VON Arx C, DI Girolamo E, Nasti G, Cavalcanti E, Tatangelo F, Romano G, Avallone A, Tafuto S.

Anticancer Res. 2017 Apr;37(4):1975-1978.

PMID:
28373469
16.

Obesity and Cancer: Biological Links and Treatment Implications.

Ottaiano A, De Divitiis C, Capozzi M, Avallone A, Pisano C, Pignata S, Tafuto S.

Curr Cancer Drug Targets. 2018;18(3):231-238. doi: 10.2174/1568009617666170330125619. Review.

PMID:
28359241
17.

Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment.

Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, Nasti G, Ottaiano A, Berretta M, Iaffaioli RV, Arra C.

Nutrients. 2017 Feb 28;9(3). pii: E210. doi: 10.3390/nu9030210.

18.

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.

Ottaiano A, Capozzi M, De Divitiis C, De Stefano A, Botti G, Avallone A, Tafuto S.

Acta Oncol. 2017 Mar;56(3):377-383. doi: 10.1080/0284186X.2017.1288922. Epub 2017 Feb 17. Review. Erratum in: Acta Oncol. 2017 Mar;56(3):499.

PMID:
28256961
19.

Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives.

Nappi A, Berretta M, Romano C, Tafuto S, Cassata A, Casaretti R, Silvestro L, Divitiis C, Alessandrini L, Fiorica F, Ottaiano A, Nasti G.

Curr Cancer Drug Targets. 2018;18(5):421-429. doi: 10.2174/1568009617666170209095143. Review.

PMID:
28183254
20.

CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients.

D'Alterio C, Nasti G, Polimeno M, Ottaiano A, Conson M, Circelli L, Botti G, Scognamiglio G, Santagata S, De Divitiis C, Nappi A, Napolitano M, Tatangelo F, Pacelli R, Izzo F, Vuttariello E, Botti G, Scala S.

Oncoimmunology. 2016 Nov 29;5(12):e1254313. doi: 10.1080/2162402X.2016.1254313. eCollection 2016.

Supplemental Content

Loading ...
Support Center